MedTrace Logo

Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor

NCT00889525 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2009-04-29

No results posted yet for this study

Summary

This study was designed to check the efficacy of a new oral medical drug treatment, namely Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma.

Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to have the D2 receptor in in vitro studies.

Conditions

  • Cushing's Disease
  • Corticotroph Adenoma

Interventions

DRUG

Cabergoline

Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.

Sponsors & Collaborators

  • Seth Gordhandas Sunderdas Medical College

    lead OTHER

Principal Investigators

  • Nalini S Shah, DM · Seth GSMC and KEM hospital, Mumbai

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00889525 on ClinicalTrials.gov